WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H563553
CAS#: 729605-21-4
Description: XRP44X is a potent Ras-Net (Elk-3) pathway inhibitor.
Hodoodo Cat#: H563553
Name: XRP44X
CAS#: 729605-21-4
Chemical Formula: C21H21ClN4O
Exact Mass: 380.14
Molecular Weight: 380.870
Elemental Analysis: C, 66.22; H, 5.56; Cl, 9.31; N, 14.71; O, 4.20
Synonym: XRP44X; XRP-44X; XRP 44X; XRP-44-X; XRP 44 X;
IUPAC/Chemical Name: 1-(3-Chlorophenyl)-4-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)carbonyl]piperazine
InChi Key: NPHPNBGYPKBDDB-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H21ClN4O/c1-16-14-20(26(23-16)18-7-3-2-4-8-18)21(27)25-12-10-24(11-13-25)19-9-5-6-17(22)15-19/h2-9,14-15H,10-13H2,1H3
SMILES Code: O=C(N1CCN(C2=CC=CC(Cl)=C2)CC1)C3=CC(C)=NN3C4=CC=CC=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 380.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Li TZ, Kim SM, Hur W, Choi JE, Kim JH, Hong SW, Lee EB, Lee JH, Yoon SK. Elk-3 Contributes to the Progression of Liver Fibrosis by Regulating the Epithelial-Mesenchymal Transition. Gut Liver. 2017 Jan 15;11(1):102-111. doi: 10.5009/gnl15566. PubMed PMID: 27538444; PubMed Central PMCID: PMC5221867.
2: Semenchenko K, Wasylyk C, Cheung H, Tourrette Y, Maas P, Schalken JA, van der Pluijm G, Wasylyk B. XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice. PLoS One. 2016 Jul 18;11(7):e0159531. doi: 10.1371/journal.pone.0159531. eCollection 2016. PubMed PMID: 27427904; PubMed Central PMCID: PMC4948895.
3: Chen J, Sun WL, Wasylyk B, Wang YP, Zheng H. c-Jun N-terminal kinase mediates microtubule-depolymerizing agent-induced microtubule depolymerization and G2/M arrest in MCF-7 breast cancer cells. Anticancer Drugs. 2012 Jan;23(1):98-107. doi: 10.1097/CAD.0b013e32834bc978. PubMed PMID: 21968419.
4: Wasylyk C, Zheng H, Castell C, Debussche L, Multon MC, Wasylyk B. Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules. Cancer Res. 2008 Mar 1;68(5):1275-83. doi: 10.1158/0008-5472.CAN-07-2674. PubMed PMID: 18316589.